Search Results for "Alnylam"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Impact of Patisiran on Health Status and Quality of Life in Patients with Transthyretin Cardiac Amyloidosis

Vutrisiran: Storage and Stability

Standard response letter on vutrisiran and storage and stability. The letter contains information on product stability when stored at a range of temperatures, photostability, and thermal cycling.

Vutrisiran: Autonomic Symptom Assessment

Standard Response Letter on vutrisiran and autonomic outcomes from the HELIOS-A study.

Exploratory Biomarker Analyses from HELIOS-B, A Phase 3 Study of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

Vutrisiran: Changes in Serum TTR Levels

Standard response letter on vutrisiran and the changes in serum TTR levels during the HELIOS-A and HELIOS-B studies.

Phase 3 HELIOS-B Study Rationale

This slide deck highlights the Phase 3 trial design for HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy.

Givosiran: Elevations in Blood Homocysteine

Standard response letter on givosiran and elevations in blood homocysteine.

Patisiran: Observation Period After Infusion

Standard Response Letter on the observational period after patisiran infusion in the APOLLO, APOLLO-B, Global OLE, and HELIOS‑A studies.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.